Volitionrx (VNRX) Equity Average (2019 - 2025)
Volitionrx (VNRX) has disclosed Equity Average for 9 consecutive years, with -$34.5 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 51.63% year-over-year to -$34.5 million, compared with a TTM value of -$34.5 million through Sep 2025, down 51.63%, and an annual FY2024 reading of -$17.4 million, down 194.11% over the prior year.
- Equity Average was -$34.5 million for Q3 2025 at Volitionrx, down from -$31.1 million in the prior quarter.
- Across five years, Equity Average topped out at $28.9 million in Q2 2021 and bottomed at -$34.5 million in Q3 2025.
- Average Equity Average over 5 years is -$3.1 million, with a median of -$143567.0 recorded in 2022.
- The sharpest move saw Equity Average skyrocketed 107.52% in 2021, then plummeted 3927.22% in 2023.
- Year by year, Equity Average stood at $19.5 million in 2021, then crashed by 100.74% to -$143567.0 in 2022, then tumbled by 3927.22% to -$5.8 million in 2023, then plummeted by 321.57% to -$24.4 million in 2024, then plummeted by 41.64% to -$34.5 million in 2025.
- Business Quant data shows Equity Average for VNRX at -$34.5 million in Q3 2025, -$31.1 million in Q2 2025, and -$27.6 million in Q1 2025.